Purchase this article with an account.
M. Taban, P. K. Kaiser, C. Y. Lowder; Outcome of Fluocinolone Acetonide Implant (RetisertTM) Re-Implantation for Chronic Non-Infectious Posterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5633.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate outcome of repeat intravitreal fluocinolone acetonide implant (RetisertTM) in patients with chronic non-infectious posterior uveitis.
Retrospective review of 10 eyes (10 patients) with recurrent non-infectious posterior uveitis who underwent a 2nd Retisert implant in the same eye. Recurrence rate of ocular inflammation in the implanted eye was evaluated before and after the 1st and 2nd implants. Surgical complications, visual acuity (VA) changes, need for adjunctive therapy, and safety were also assessed.
After 1st Retisert implantation, the VA was stable or improved in 100% of patients and the median time to first recurrence was 32.5 months (range, 17.5-54 months). After 2nd implantation, the median follow-up was 16.8 months, the VA was stable or improved in 100% of patients, and only 4 eyes had recurrences during the follow-up period (median 18.3 months, range 11-29.5 months). Of the 4 phakic eyes prior to 1st implant, all had underwent cataract extraction (range 8.5 to 16.5 months). Five eyes required glaucoma surgery after the 1st implant and one eye after the 2nd implant. Other complications included one case of vitreous hemorrhage after 1st implant and one rhegmatogenous retinal detachment (RRD) at the site of 2nd implant.
Retisert re-implantation for chronic non-infectious posterior uveitis offers similar control of ocular inflammation as the 1st implantation with recurrence occurring at approximately 1.5 to 2 years. Complications in the second implant are similar to those reported after primary implantation.
This PDF is available to Subscribers Only